Overview

Cardiovascular Diseases and Diabetes Prevention Programme in Metabolic Syndrome (CDPP)

Status:
Not yet recruiting
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
The metabolic syndrome population is at high-risk of cardiovascular diseases and diabetes. How to effectively control the risk factors of this population is the key to primary prevention of cardiovascular diseases and diabetes in China. This study aims to explore the efficacy and safety of an intervention strategy with berberine that can effectively treat a variety of risk factors (hyperglycemia, dyslipidemia, hypertension).
Phase:
Phase 4
Details
Lead Sponsor:
Tang Yida
Collaborator:
Chinese Society of Cardiology